Lead Sponsor

Novo Nordisk A/S

Age

All ages

Sex

ALL

Healthy Volunteers

No

•Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
•The decision to initiate treatment with commercially available Ozempic® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
•Patients with Diabetes Mellitus, Type 2 (T2DM) who the physician has decided to start treatment with Ozempic®.
•Male or female, no age limitation.

•Previous participation in this study. Participation is defined as having given informed consent in this study.
•Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
•Patients who fall under contraindications to the label.
•Patients who are or have previously been treated with Ozempic®.
•Female who is pregnant, breast-feeding or intends to become pregnant.